AutoSet for Her Quality of Life Clinical Trial
AutoSet for Her Quality of Life Clinical Trial
Obstructive sleep apnea (OSA) has detrimental effects on the health and quality of life of
 suffers. Recent literature has shown that females may be particularly susceptible to adverse
 the quality of life effects, and that female obstructive sleep apnea manifests differently
 than male obstructive sleep apnea. A new AutoSetting Positive Airway Pressure (PAP) device
 has been designed specifically to treat female OSA. In this Cohort study, female patients who
 are newly diagnosed with OSA will be asked to complete various questionnaires relating to
 their quality of life. Patients will then use the AutoSet for Her for three months. At the
 completion of the three months the questionnaires will be repeated. Before treatment and
 after treatment quality of life will be compared to determine if treating female specific OSA
 in these patients improves quality of life.
Inclusion Criteria:

 -  Females aged ≥ 18 years

 -  Diagnostic PG/ PSG showing at least moderate OSA (AHI ≥ 15)

 -  Indication for PAP

 -  Participants willing and able to give written informed consent

 -  Ability to tolerate PAP therapy

 Exclusion Criteria:

 -  Participants currently using CPAP or who have previous experience with CPAP

 -  Participants currently using supplemental oxygen

 -  Participants who are pregnant or planning to become pregnant in the next 3 months